- Home
- CMS vs ILMN Comparison
CMS vs ILMN Comparison
Compare CMS & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMS
- ILMN
- Stock Information
- Founded
- CMS 1987
- ILMN 1998
- Country
- CMS United States
- ILMN United States
- Employees
- CMS N/A
- ILMN N/A
- Industry
- CMS Power Generation
- ILMN Medical Specialities
- Sector
- CMS Utilities
- ILMN Health Care
- Exchange
- CMS Nasdaq
- ILMN Nasdaq
- Market Cap
- CMS 22.5B
- ILMN 18.9B
- IPO Year
- CMS N/A
- ILMN 2000
- Fundamental
- Price
- CMS $73.89
- ILMN $123.26
- Analyst Decision
- CMS Buy
- ILMN Hold
- Analyst Count
- CMS 12
- ILMN 15
- Target Price
- CMS $79.00
- ILMN $114.93
- AVG Volume (30 Days)
- CMS 2.9M
- ILMN 2.1M
- Earning Date
- CMS 10-30-2025
- ILMN 10-30-2025
- Dividend Yield
- CMS 2.93%
- ILMN N/A
- EPS Growth
- CMS N/A
- ILMN N/A
- EPS
- CMS 3.47
- ILMN 4.46
- Revenue
- CMS $8,295,000,000.00
- ILMN $4,288,000,000.00
- Revenue This Year
- CMS $8.81
- ILMN N/A
- Revenue Next Year
- CMS $4.13
- ILMN $2.22
- P/E Ratio
- CMS $21.34
- ILMN $27.76
- Revenue Growth
- CMS 10.96
- ILMN N/A
- 52 Week Low
- CMS $63.97
- ILMN $68.70
- 52 Week High
- CMS $76.45
- ILMN $153.06
- Technical
- Relative Strength Index (RSI)
- CMS 51.49
- ILMN 64.52
- Support Level
- CMS $72.58
- ILMN $117.86
- Resistance Level
- CMS $75.09
- ILMN $126.94
- Average True Range (ATR)
- CMS 1.05
- ILMN 4.62
- MACD
- CMS -0.05
- ILMN -0.31
- Stochastic Oscillator
- CMS 62.52
- ILMN 66.58
About CMS CMS Energy Corporation
CMS Energy is an energy holding company with three principal businesses. Its regulated utility, Consumers Energy, provides regulated natural gas service to 1.8 million customers and electric service to 1.9 million customers in Michigan. NorthStar Clean Energy, formerly CMS Enterprises, is engaged in wholesale power generation, including contracted renewable energy. CMS sold EnerBank in October 2021.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.